Here are five things to know:
1. Some states have implemented prescriber restrictions that make it more difficult for patients to receive the hepatitis C drugs without involving a subspecialist.
2. The AAFP and seven other organizations sent a joint letter to Andy Slavitt, the acting administrator for CMS, on April 18 urging his agency to revise its policies so patients who need hepatitis C drugs have access to physicians who can prescribe them.
3. Previously, patients with hepatitis C were typically treated with self-injections of interferon which, according to the joint letter, had terrible side effects, only a 50 percent cure rate and cost between $15,000 to $20,000.
4. The hepatitis C drug Harvoni, a daily oral pill, has a cure rate of 90 percent and few side effects, but each pill costs $1,125, which translates to $94,500 for three months of treatment or $189,000 for six months.
5. According to a study published in the journal Annals of Internal Medicine, 29 states have implemented restrictions based on prescriber type. Fourteen of these states require the prescriber to be a specialist in gastroenterology, hepatology, infectious diseases or liver transplantation. The remaining 15 states allow treatment decisions only after consultations with a specialist.
More articles on GI & endoscopy:
FDA approves 1st CRC screening blood test, LifeBond’s GI-related sealant receives CE Mark & more — 7 GI company key notes
Aspirin use may lower risk of bile duct cancer: 3 observations
Nor-ursodeoxycholic acid shows success in treating primary sclerosing cholangitis — 3 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
